A Phase 0 Study to Assess the Safety and Biodistribution of a Novel Radiolabeled Antibody Targeting Human Kallikrein-2 (hk2) in Subjects With Metastatic Castration-resistant Prostate Cancer
Latest Information Update: 27 Sep 2023
At a glance
- Drugs 111-indium labelled h 11B6-Invicro/Janssen Research and Development (Primary) ; H 11B6
- Indications Adenocarcinoma; Prostate cancer
- Focus First in man; Pharmacokinetics
- Sponsors Tomopath Inc.
Most Recent Events
- 21 Sep 2023 Status changed from recruiting to discontinued.
- 08 Apr 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 08 Apr 2021 Planned primary completion date changed from 30 Dec 2020 to 30 Dec 2021.